Although the diagnosis of T2DM is straightforward, it is extremely difficult to monitor and to treat successfully long-term. Therapy and the monitoring of its effectiveness are complex, invasive, and expensive. Lack of patient education and resources compounds the problem and contributes to non-compliance and suboptimal glycemic control. The asymptomatic nature of chronic hyperglycemia does not allow the patient to truly understand the risk of diabetic complications until irreversible damage has developed. Therapies that have been added to available options in recent years have new and different mechanisms of action. However, when used as monotherapy, none of them (save insulin and its analogs) sustain optimal control for long intervals of time in the majority of patients.
Was this article helpful?